How Estrogen Exposure and Hormone Therapy Protect Brain Health and Vascular Integrity in Women

Longer Reproductive Years and Hormone Therapy Linked to Brain Blood Vessel Health

A new population-based longitudinal investigation published in Neurology has found that greater lifetime estrogen exposure and hormone therapy preserve neurovascular health while reducing cerebral small vessel disease in aging women. The research, drawn from data on 352 cognitively unimpaired 70-year-old women in the Gothenburg H70 Birth Cohort Studies born in 1944, sheds light on how hormonal milestones across a woman’s lifespan interact with brain aging.

As ScienceAlert reported, neurobiologist Anna Marseglia of the Karolinska Institutet noted that hormonal exposure across different life periods appears to carry cumulative effects for cerebrovascular health later in life. Each additional year of reproductive lifespan—calculated as age at natural menopause minus age at menarche—corresponded with about an 8 percent decrease in the odds of having two or more signs of small vessel disease at age 70. Researchers observed that a later age at natural menopause served as the dominant driver of this protection, whereas the age at menarche showed no significant association.

Hormonal Therapies Preserve White Matter Integrity

Beyond natural reproductive milestones, exogenous hormonal therapies provided distinct cerebrovascular benefits across different life stages. Insights spotlighted by Brain and Life Magazine revealed that taking oral contraceptives during reproductive years, alongside menopausal hormone therapy during the menopausal transition, both linked to notably elevated fractional anisotropy, which points to healthier white matter across forty-eight major cerebral pathways.

How Estrogen Exposure and Hormone Therapy Protect Brain Health and Vascular Integrity in Women — Photo: ScienceAlert

Menopausal hormone therapy specifically associated with a lower total burden of cerebral small vessel disease, reducing the odds of enlarged basal ganglia perivascular spaces and cerebral microbleeds. The highest level of white matter preservation and the minimal likelihood of severe vascular complications were found among female participants who used both oral contraceptives and menopausal hormone therapy in contrast to those who used neither. Over a five-year observation period, follow-up evaluations demonstrated consistent cortical thickness trends alongside a downward shift regarding white matter hyperintensity accumulation among individuals using hormone therapy.

Genetics Reveal Diverging Neurodegenerative Markers

The study also evaluated genetic susceptibility through the apolipoprotein-ε4 (APOE-ε4) gene variant, which increases an individual’s risk of developing Alzheimer’s disease. Researchers discovered an intriguing divergence between vascular and neurodegenerative markers. While lifelong estrogen exposure did not correlate with global Alzheimer disease cortical thickness across the entire cohort, menopausal hormone therapy associated with preserved cortical thickness in Alzheimer-vulnerable regions exclusively among APOE-ε4 carriers. Conversely, favorable cerebrovascular associations with small vessel disease and white matter integrity proved most pronounced among noncarriers.

The Center for Biomedical and Brain Imaging is where the Mechanical Neuroimaging Lab is located. This 11 — Photo: Delaware Public Media

Because the investigation is observational, the results cannot establish direct cause and effect. Yet, for practicing physicians evaluating cerebrovascular vulnerability and individualized dementia risk, understanding how estrogen exposure and brain health intersect provides vital clinical rationale for incorporating lifetime hormonal history into patient assessments.